Clinical significance of defective dendritic cell differentiation in cancer.

By B. Almand, J. R. Resser, B. Lindman, S. Nadaf, Joseph I. Clark, E. Kwon, D. Carbone, D. Gabrilovich. Clinical Cancer Research, 2000

763 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/19c244bc4b9351feea30b622abf53663667416e0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Lung cancer: Biology and treatment options. (2015, background): “However, in the tumor microenvironment, DCs are often in an immature state that fail to prime T-cells efficiently due to low expression levels of co-stimulatory molecules such as CD80 and CD86 and a weak antigen presenting capacity [60,61].”
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 (2001, background): “As reported earlier, the cells in the DC fraction from patients with advanced cancer demonstrated a profound defect in their ability to stimulate allogeneic T cells (8, 13).”
Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “We have demonstrated an increase in the total DC population in patients with breast and prostate cancer after surgery (147).”
The tumor microenvironment and its role in promoting tumor growth (2008, background): “Further, maturation defects in DC of patients with cancer have been described (Almand et al., 2000) and are attributable, in part, to vascular endothelial growth factor (VEGF) production by human tumors (Gabrilovich et al.”
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression (2010, background): “In addition, Gr-1+CD11b+ cells produce a high level of TGF-β and correlates with stage of tumor progression [84].”
Vascular Endothelial Growth Factor and Angiogenesis (2004, background): “Removal of the source of these factors by surgical excision restores the process of DC differentiation and results in higher numbers of DC in the circulation (Almand et al., 2000).”
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (2008, background): “Subsequent phenotyping of Lin−/Lo HLA DR− cells have revealed that they are also positive for both CD33+ and CD11b+ [1, 12].”
Mechanisms of immune evasion by tumors. (2006, background): “, and Gabrilovich, D. I. (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55, 1–9. Kusmartsev, S., Nefedova, Y., Yoder, D., and Gabrilovich, D. I. (2004). Antigen‐specific inhibition of CD8þ T cell response by immature myeloid cells in can”